Merit Financial Group’s Annovis Bio ANVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-81,316
Closed -$181K 2365
2026
Q1
$181K Hold
81,316
﹤0.01% 1951
2025
Q4
$281K Hold
81,316
﹤0.01% 1599
2025
Q3
$168K Sell
81,316
-10,000
-11% -$25K ﹤0.01% 1699
2025
Q2
$198K Sell
91,316
-6,500
-7% -$12.8K ﹤0.01% 1570
2025
Q1
$147K Sell
97,816
-700
-0.7% -$2.14K ﹤0.01% 1335
2024
Q4
$496K Buy
98,516
+71,816
+269% +$520K 0.01% 731
2024
Q3
$215K Buy
26,700
+5,000
+23% +$46.8K ﹤0.01% 768
2024
Q2
$125K Sell
21,700
-500
-2% -$4.05K ﹤0.01% 885
2024
Q1
$115K Hold
22,200
﹤0.01% 839
2023
Q4
$415K Sell
22,200
-19,000
-46% -$168K 0.01% 533
2023
Q3
$391K Sell
41,200
-1,200
-3% -$14.8K 0.01% 513
2023
Q2
$606K Sell
42,400
-500
-1% -$7.07K 0.02% 423
2023
Q1
$661K Sell
42,900
-250
-0.6% -$4.04K 0.02% 350
2022
Q4
$580K Buy
43,150
+23,150
+116% +$289K 0.02% 392
2022
Q3
$274K Buy
+20,000
New +$263K 0.01% 460

Other funds holding ANVS

Merit Financial Group's ANVS Position: Q2 2026 in Review

Merit Financial Group sold out of Annovis Bio (ANVS) in Q2 2026, closing a stake of 81,316 shares — an estimated $181K sold.

Merit Financial Group first reported a position in ANVS in Q3 2022 and held it in 15 quarters. The position peaked at $661K in Q1 2023. 13 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • Merit Financial Group reported no remaining Annovis Bio position as of Q2 2026 after selling out during the quarter.
  • Merit Financial Group sold 81,316 Annovis Bio shares in Q2 2026, an estimated $181K.
  • Merit Financial Group first reported a position in Annovis Bio in Q3 2022 and held it in 15 quarters.
  • Merit Financial Group's Annovis Bio position peaked at $661K in Q1 2023.
  • 13 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.